Bounded scope
A defined claim sample agreed before work begins. No open-ended review, no scope drift.
Entry product
A focused, dated intelligence review for teams that need to understand exposure before commissioning a broader assessment.
$1,500–$2,500, depending on the number of surfaces and claims in scope.
Purpose
“Is there enough here to justify a deeper review?”
It is deliberately bounded. A defined sample of public claims, tested against visible evidence, with the findings dated and sourced. Enough to make the next decision responsibly — not a full assessment, and not presented as one.
A defined claim sample agreed before work begins. No open-ended review, no scope drift.
Every observation carries its source and the date it was captured, so the finding stays checkable.
The output either justifies a broader assessment or it does not. Both are useful answers.
Deliverables
One dated file, sized to be read in a sitting and forwarded without explanation.
Where it leads
Most Diagnostics resolve one of three ways. Each has a defined next step, and none of them is a sales call you cannot decline.
A small number of claims need substantiation or rewriting. You take the safer language examples and handle it internally.
The sample suggests the pattern repeats across entities or locations. An Enterprise Exposure Assessment is the proportionate next step.
The findings bear on a pending deal. AI & Regulatory Diligence scopes the full target surface against the transaction calendar.
The instrument behind it
The Diagnostic is produced using AuditGPT, the public-claim diagnostic instrument powered by Scrutexity. The instrument captures and structures the claim surface; the analysis, confidence labels, and priority findings are reviewed by a person before anything is delivered.
Boundaries
Next step
Tell us which surfaces you want sampled and what decision the result needs to support.